CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($) shares in Millions, $ in Millions |
3 Months Ended | 6 Months Ended | ||||||
|---|---|---|---|---|---|---|---|---|
Jun. 28, 2026 |
Jun. 29, 2025 |
Jun. 28, 2026 |
Jun. 29, 2025 |
|||||
| Alliance revenues | $ 2,697 | $ 2,273 | $ 5,036 | $ 4,386 | ||||
| Total revenues | 15,034 | 14,653 | 29,484 | 28,367 | ||||
| Costs and expenses: | ||||||||
| Cost of sales | [1] | 4,092 | 3,778 | 7,640 | 6,624 | |||
| Selling, informational and administrative expenses | [1] | 3,411 | 3,415 | 6,372 | 6,446 | |||
| Research and development expenses | [1] | 2,809 | 2,482 | 5,299 | 4,685 | |||
| Acquired in-process research and development expenses | 16 | 2 | 153 | 11 | ||||
| Amortization of intangible assets | 1,185 | 1,211 | 2,368 | 2,421 | ||||
| Restructuring charges and certain acquisition-related costs | 457 | (18) | 557 | 660 | ||||
| Other (income)/deductions––net | 3,716 | 739 | 4,577 | 1,692 | ||||
| Income/(loss) from continuing operations before provision/(benefit) for taxes on income/(loss) | [2] | (653) | 3,044 | 2,517 | 5,828 | |||
| Provision/(benefit) for taxes on income/(loss) | (407) | 141 | 54 | (48) | ||||
| Income/(loss) from continuing operations | (246) | 2,903 | 2,463 | 5,876 | ||||
| Discontinued operations––net of tax | 8 | 25 | (5) | 25 | ||||
| Net income/(loss) before allocation to noncontrolling interests | (237) | 2,928 | 2,458 | 5,901 | ||||
| Less: Net income attributable to noncontrolling interests | 10 | 18 | 19 | 24 | ||||
| Net income/(loss) attributable to Pfizer Inc. common shareholders | $ (248) | $ 2,910 | $ 2,440 | $ 5,877 | ||||
| Earnings/(loss) per common share––basic: | ||||||||
| Income /loss) from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share) | $ (0.04) | $ 0.51 | $ 0.43 | $ 1.03 | ||||
| Discontinued operations––net of tax (in dollars per share) | 0 | 0 | 0 | 0 | ||||
| Net income/(loss) attributable to Pfizer Inc. common shareholders (in dollars per share) | (0.04) | 0.51 | 0.43 | 1.03 | ||||
| Earnings/(loss) per common share––diluted: | ||||||||
| Income/(loss) from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share) | (0.04) | 0.51 | 0.43 | 1.03 | ||||
| Discontinued operations––net of tax (in dollars per share) | 0 | 0 | 0 | 0 | ||||
| Net income/(loss) attributable to Pfizer Inc. common shareholders (in dollars per share) | $ (0.04) | $ 0.51 | $ 0.43 | $ 1.03 | ||||
| Weighted-average shares--basic (in shares) | 5,699 | 5,685 | 5,695 | 5,680 | ||||
| Weighted-average shares--diluted (in shares) | 5,699 | 5,706 | 5,733 | 5,708 | ||||
| Product [Member] | ||||||||
| Revenues | $ 11,863 | $ 11,954 | $ 23,578 | $ 23,248 | ||||
| Royalty [Member] | ||||||||
| Revenues | $ 474 | $ 426 | $ 870 | $ 734 | ||||
| ||||||||
| X | ||||||||||
- Definition The amount of amortization that is not associated with a single function. Amounts associated in a single function are included in Cost of sales, Selling, information and administrative expenses and Research and development expenses. No definition available.
|
| X | ||||||||||
- Definition This element represents (i) restructuring charges, which are amounts charged against earnings in the period for incurred and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a program that is planned and controlled by management, and materially changes either the scope of a business undertaken by an entity, or the manner in which that business is conducted; and (ii) acquisition-related costs, which are costs incurred to effect a business combination which costs have been expensed during the period. Such costs can include transaction costs such as banking, legal, accounting and other costs directly related to effect a business combination as well as external, incremental costs of integration planning that are directly related to a business combination, including costs associated with preparing for systems and other integration activities. No definition available.
|
| X | ||||||||||
- Definition The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of Net Income (Loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of income (expense) related to nonoperating activities, classified as other. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of writeoff for research and development asset acquired in transaction other than business combination or from joint venture formation or both. Includes, but is not limited to, software to be sold, leased, or marketed. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|